Prashanth Varkey

Prashanth Varkey

Auto-generated profile, based on publicly available information

Prashanth Varkey

Department of Research and Development, Zum Heilen Diagnostic and Therapeutics Pvt. Ltd., Idukki, Kerala, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
AAAsina Palakuzhy Abdurahman
Asina Palakuzhy Abdurahman
PVPrashanth Varkey
Prashanth Varkey
JKJacob Kuruvilla
Jacob Kuruvilla
VCVidya Koncheri Churray
Vidya Koncheri Churray
SNSilpa Kannanpallil Narayanan
Silpa Kannanpallil Narayanan
HSHarish Kumar Kaleeckal Sadanandan
Harish Kumar Kaleeckal Sadanandan
Background: Urinary tract infections (UTIs) are some of the most commonly encountered infections in clinical practice that affects 150 million people each year worldwide. The emergence of resistance, adverse effects of antimicrobial agents, and other related issues have prompted the establishment of a research framework to explore alternative methods for managing UTIs. Cardamom exhibits unique botanical characteristics and biochemical compositions, contributing to their diverse culinary and medicinal applications. Techniques like gas chromatography-mass spectrometry analysis have identified 1,8-cineole and a-terpineol as main bioactive components in both black and green cardamom. Present study addresses urgent, unmet analytical and clinical care needs by exploring adoption of alternative therapies, specifically nutraceuticals viz, 1, 8-cineole and α-terpineol, major bioactive from cardamon for controlling and treating UTIs. Methods: Different concentrations of 1,8-cineole, α-terpineol and 1,8-cineole/α-terpineol (1:1) were used to determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against multi-drug resistant (MDR) E. coli isolated from UTIs. Results: The mean MIC and MBC of 1,8-cineole, α-terpineol and 1,8-cineole/α-terpineol (1:1) for MDR E. coli strains were 7.73 µg/ml, 0.32 µg/ml and 0.32 µg/ml respectively. For non MDR E. coli strains the mean MIC and MBC of the 1, 8-cineole, α-terpineol and 1,8-cineole/α-terpineol (1:1) were 2.14 µg/ml, 0.2 µg/ml and the 0.2 µg/ml respectively. Conclusions: 1,8-cineole and α-terpineol exhibited good antimicrobial activity against urinary E. coli isolates tested, including MDR strains.

7 September 2023 in Journal of Advanced Oral Research
Verified
Journal Article
Closed access
MTMatthan Tharakan
Matthan Tharakan
MKManohar Suresh Kugaji
Manohar Suresh Kugaji
KBKishore Bhat
Kishore Bhat
PVPrashanth Varkey
Prashanth Varkey
MJMayuri Joshi
Mayuri Joshi
BNBhagyashree Nanda
Bhagyashree Nanda
Aim: Oral candidiasis is a fungal infection of the oral cavity caused by Candida albicans. Currently used antifungal drugs fail to treat oropharyngeal candidiasis. Herbal remedies are found to be safe and effective to treat bleeding gums, halitosis, mouth ulcers, and reduce tooth decay. Cardamom is known to possess antimicrobial, antioxidant, and immunomodulatory activity. In an in vitro study, we aim to evaluate the antifungal potential of cardamom-based Denteez TM mouthwash against opportunistic fungal infections in the oral cavity. Materials and Methods: Five Candida species were included in the study: namely C. albicans, C. tropicalis, C. krusei, C. parapsilosis, and C. glabrata. Additionally, 54 clinical isolates obtained from oral cavity of healthy individuals and patients suffering from oral candidiasis were randomly selected and included. Various antifungal agents tested included fluconazole, itraconazole, ketoconazole, miconazole, and amphotericin B. Minimum inhibitory concentration (MIC) and time-kill assay were performed as per standard guidelines. Results: The MIC obtained for fluconazole against different Candida species was 1.25 µg/ml. The MIC of azole drugs was in the range of 0.312–0.62 µg/ml. The MIC of Denteez TM mouthwash was determined as 1.25%. The clinical isolates of Candida showed major resistance to fluconazole (75.9%) and absolute susceptibility to amphotericin B. Denteez TM was found effective in inhibiting 98.2% of the clinical isolates. Denteez TM mouthwash showed time-dependent inhibition of all Candida species. Conclusion: The mouthwash has comparable efficacy to that of other routinely used antifungal agents. Denteez TM can be effectively used to deal with oral candidiasis and antifungal resistance.